

Analytical Biochemistry Volume 616, 1 March 2021, 114088



Technical note

Inhibition of lysosomal vacuolar proton pump down-regulates cellular acidification and enhances *E. coli* bactofection efficiency

Rasaq Olajide Akinsola ª, Choon Weng Lee ^b, Edmund Ui Hang Sim ^c, Kumaran Narayanan ª Ӓ 🖾

- ^a School of Science, Monash University Malaysia, Bandar Sunway, 47500, Selangor Darul Ehsan, Malaysia
- ^b Institute of Biological Sciences, University of Malaya, 50603, Kuala Lumpur, Malaysia
- ^c Faculty of Resource Science and Technology, Universiti Malaysia Sarawak, 94300, Sarawak, Malaysia

Received 18 September 2020, Revised 4 December 2020, Accepted 17 December 2020, Available online 25 December 2020.

Check for updates

Show less 🔨

+ Add to Mendeley 🚓 Share 🌗 Cite

https://doi.org/10.1016/j.ab.2020.114088

Get rights and content

Highlights

- Bactofection efficiency is constrained by cellular barriers such as plasma membrane, endosomal escape and nuclear entry.
- Bafilomycin A₁, a specific inhibitor of the lysosomal H⁺ vacuolar proton pump, decreases the cellular acidification.
- Low acidification likely assists E. coli's endosomal escape.
- Cells pre-treated with bafilomycin A₁ achieved significantly higher gene delivery by the E. coli vector.

ARTICLE IN PRESS

Analytical Biochemistry xxx (xxxx) xxx



Contents lists available at ScienceDirect

Analytical Biochemistry



journal homepage: www.elsevier.com/locate/yabio

Technical note

Inhibition of lysosomal vacuolar proton pump down-regulates cellular acidification and enhances *E. coli* bactofection efficiency

Rasaq Olajide Akinsola^a, Choon Weng Lee^b, Edmund Ui Hang Sim^c, Kumaran Narayanan^{a,*}

^a School of Science, Monash University Malaysia, Bandar Sunway, 47500, Selaneor Darul Ehsan, Malaysia

^b Institute of Biological Sciences, University of Malaya, 50603, Kuala Lumpur, Malaysia

^c Faculty of Resource Science and Technology, Universiti Malaysia Sarawak, 94300, Sarawak, Malaysia

ARTICLE INFO	A B S T R A C T
<i>Keywords:</i> Proton pump inhibitor Endosome Bacteria DNA delivery Lysosome V-ATPase Endocytosed	Endosomal escape is considered a crucial barrier that needs to be overcome by integrin-mediated <i>E. coli</i> for gene delivery into mammalian cells. Bafilomycin, a potent inhibitor of the H+ proton pump commonly employed to lower endosomal pH, was evaluated as part of the <i>E. coli</i> protocol during delivery. We found an increase in green fluorescent protein expression up 6.9, 3.2, 5.0, 2.8, and 4.5 fold in HeLa, HEK-293, A549, HT1080, and MCF-7 respectively, compared to untreated cells. Our result showed for the first time that Inhibition of lysosomal V-ATPase enhances <i>E. coli</i> efficiency.

1. Introduction

E. coli-based vectors commonly utilize exogenous genes such as invasin from *Yersinia pseudotuberculosis* and listeriolysin O from *Listeria monocytogene*, to enable the transfer of expression plasmids into eukaryotic cells [1–3]. However, the transfection efficiency of *E. coli* vectors has generally been low compared to viral vectors due to several cellular barriers [4], including cellular uptake of the vector, endosomal escape, and nuclear entry.

Of these, endosomal escape has been one of the major pitfalls that limit the endocytosed *E. coli* vectors from achieving higher gene delivery efficiencies [5]. Like other non-viral vector, the inability of the endocytosed *E. coli* vector to escape the endosome will result in lysosomal degradation. Lysosomal degradation is suggested to be as a result of decreasing intracellular pH as the vector navigates through the endolysosomal compartment [6]. Therefore, overcoming this lysosomal barrier by inhibiting its acidification could potentially enable our vector to deliver gene at a much higher rate. To the best of our knowledge, inhibition of the lysosomal acidification has not been tested as a method to improve the efficiency of gene transfer by the *E. coli* vector.

In a previous study, neutralization of the endosome and lysosome was achieved by lysosomotropic drug chloroquine that increased the efficiency of *E. coli* delivery by 6-fold in B16F10 cells [7]. This endosomal enhancer induced swelling of the endosome and prevented the fusion of the endosome to the lysosome without any effect on the

vacuolar proton-translocating ATPases (V-ATPase).

The lysosomal V-ATPase is responsible for the continuous production of hydrolase that plays a crucial role in the acidification of the endosome and degradation of the internalized vector [8-10].

Based on these observations, we hypothesized that inhibiting the V-ATPase would decrease lysosomal acidification, resulting in a significant increase in *E. coli* gene delivery efficiency. To test this, we pre-incubated cells with bafilomycin A_1 , a macrolide antibiotic that is known to inhibit the vacuolar-type H⁺-ATPases, before invasion with the *E. coli* vector [11–13]. Specifically, HeLa, HT1080, HEK-293, A549 and MCF-7 cells were incubated with DMEM containing 1/100 volume of bafilomycin A_1 dissolved in DMSO for 1 h at 37 °C in a 5% of CO₂ atmosphere. Bafilomycin A_1 was prepared by reconstitution in DMSO before it was utilized. DMSO was used as a positive control in this experiment. DMSO is considered a small amphiphile that enhances cell permeability and works as a tool for drug delivery into mammalian cells [14].

Next, the cells were invaded with our *E. coli* vector carrying a pEGFP-N2 plasmid that contains a GFP reporter driven by a mammalian CMV promoter, using our established invasion protocol [1]. Cells were presented with *E. coli* at 1000 multiplicity of infection (MOI) in 6 well plates and centrifuged for 10 min at $250 \times g$ before incubation for 1 h. This was followed by treatment with 80 µg/ml of gentamicin to selectively kill the extracellular *E. coli* for 1 h, after which the plates were incubated for 48 h with DMEM containing 20 µg/ml of gentamicin.

To determine the gene delivery efficiency of E. coli vector,

* Corresponding author. *E-mail address:* kumaran.narayanan@monash.edu (K. Narayanan).

https://doi.org/10.1016/j.ab.2020.114088

Received 18 September 2020; Received in revised form 4 December 2020; Accepted 17 December 2020 0003-2697/© 2020 Elsevier Inc. All rights reserved.